Literature DB >> 26622625

Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Youssef Al-Tonbary1, Mohamed Badr2, Ahmed Mansour1, Usama El Safy2, Shebl Saeed3, Tamer Hassan2, Rasha Elashery1, Rofida Nofal2, Ahmad Darwish1.   

Abstract

Neuroblastoma, an embryonal malignancy of the sympathetic nervous system, is the most frequent extracranial solid tumor The clinico-epidemiological features of neuroblastoma in infants and children were investigated between January 2005 and January 2010 at the Pediatric Oncology units of Mansoura, Zagazig, and Tanta University Children's Hospitals (Egypt). Of 142 cases of neuroblastoma, 10 were omitted from the study due to defective data. The median age of the patients was 30 months, with 75.8% aged ≥1 year and 24.2% aged <1 year at time of diagnosis. The male-to-female ratio was 1.06. Suprarenal glands were the most common primary tumor site (72.7%). The majority of the patients (76.7%) had stage IV disease. Favorable pathology was observed in 43.8% of patients, while 56.2% exhibited unfavorable pathology. The estimated survival rate of patients was 30.7±10.0%, and mean survival time was 24.2±5.2 months. The rate of mortality was 28.6% for patients aged <1 year, and 81.8% for those aged ≥1 year (P=0.005). For patients with favorable pathology, the rate of mortality was significantly lower (28.6%) compared with that of patients with unfavorable pathology (77.8%; P=0.049). Although the association between outcome and each of the primary tumor sites, children's oncology group risk and gender was statistically insignificant, a large effect size was identified between outcome and primary tumor site, as well as children's oncology group risk and a medium effect size was identified between outcome and gender. Additionally, an age of ≥1 year was associated with unfavorable pathology (P=0.024), stage IV disease (P=0.026) and a suprarenal primary tumor site (P=0.001).

Entities:  

Keywords:  epidemiology; neuroblastoma

Year:  2015        PMID: 26622625      PMCID: PMC4509073          DOI: 10.3892/ol.2015.3335

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.

Authors:  K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Authors:  H Shimada; S Umehara; Y Monobe; Y Hachitanda; A Nakagawa; S Goto; R B Gerbing; D O Stram; J N Lukens; K K Matthay
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

3.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

4.  Neuroblastoma: treatment outcome after incomplete resection of primary tumors.

Authors:  Suk-Bae Moon; Kwi-Won Park; Sung-Eun Jung; Woong-Jae Youn
Journal:  Pediatr Surg Int       Date:  2009-07-21       Impact factor: 1.827

5.  Neuroblastoma, its natural history and prognosis: a study of 487 cases.

Authors:  L M Wilson; G J Draper
Journal:  Br Med J       Date:  1974-08-03

6.  Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology.

Authors:  Gabor Méhes; Andrea Luegmayr; Rosa Kornmüller; Ingeborg M Ambros; Ruth Ladenstein; Helmut Gadner; Peter F Ambros
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

7.  Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases.

Authors:  N L Carlsen; I J Christensen; H Schroeder; P V Bro; G Erichsen; B Hamborg-Pedersen; K B Jensen; O H Nielsen
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860

Review 8.  Neuroblastoma: biology and molecular and chromosomal pathology.

Authors:  Manfred Schwab; Frank Westermann; Barbara Hero; Frank Berthold
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

9.  Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

Authors:  B De Bernardi; V Mosseri; H Rubie; V Castel; A Foot; R Ladenstein; G Laureys; M Beck-Popovic; A F de Lacerda; A D J Pearson; J De Kraker; P F Ambros; Y de Rycke; M Conte; P Bruzzi; J Michon
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

10.  Epidemiological and some clinical characteristics of neuroblastoma in Mexican children (1996-2005).

Authors:  Servando Juárez-Ocaña; Virginia Palma-Padilla; Guadalupe González-Miranda; Alicia Georgina Siordia-Reyes; Enrique López-Aguilar; Martha Aguilar-Martínez; Juan Manuel Mejía-Aranguré; Rogelio Carreón-Cruz; Mario Enrique Rendón-Macías; Arturo Fajardo-Gutiérrez
Journal:  BMC Cancer       Date:  2009-08-03       Impact factor: 4.430

View more
  4 in total

1.  A practical solution to estimate the sample size required for clinical prediction models generated from observational research on data.

Authors:  Carlos Baeza-Delgado; Leonor Cerdá Alberich; José Miguel Carot-Sierra; Diana Veiga-Canuto; Blanca Martínez de Las Heras; Ben Raza; Luis Martí-Bonmatí
Journal:  Eur Radiol Exp       Date:  2022-06-01

2.  Seasonal trends of diagnosis of childhood malignant diseases and viral prevalence in South Korea.

Authors:  Kyu Seok Shim; Min Hyung Kim; Choong Nam Shim; Minkyu Han; In Seok Lim; Soo Ahn Chae; Sin Weon Yun; Na Mi Lee; Dae Yong Yi; Hyery Kim
Journal:  Cancer Epidemiol       Date:  2017-11-08       Impact factor: 2.984

3.  Neuroblastoma Among Omani Children: Clinical characteristics and survival outcome from a dedicated centre.

Authors:  Abeer Al-Battashi; Ameera Al-Rahbi; Abdulhakeem Al-Rawahi; Mohammed Mamdouh; Ibrahim Al-Ghaithi; Fatma A Ramadhan
Journal:  Sultan Qaboos Univ Med J       Date:  2021-11-25

4.  Transcription factor activity of estrogen receptor α activation upon nonylphenol or bisphenol A treatment enhances the in vitro proliferation, invasion, and migration of neuroblastoma cells.

Authors:  Hongda Ma; Yao Yao; Changli Wang; Liyu Zhang; Long Cheng; Yiren Wang; Tao Wang; Erguang Liang; Hui Jia; Qinong Ye; Mingxiao Hou; Fan Feng
Journal:  Onco Targets Ther       Date:  2016-06-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.